metricas
covid
Buscar en
Open Respiratory Archives
Toda la web
Inicio Open Respiratory Archives Evolution of Radiologic Alterations in Patients With Covid-19 Pneumonia and Fibr...
Journal Information
Visits
370
Vol. 7. Issue 1.
(January - March 2025)
Scientific letter
Full text access
Evolution of Radiologic Alterations in Patients With Covid-19 Pneumonia and Fibrosis at 6 Months
Evolución de las alteraciones radiológicas en pacientes con neumonía covíd-19 y presencia de fibrosis a los 6 meses
Visits
370
Selene Cuenca Perisa,
Corresponding author
selenecp@gmail.com

Corresponding author.
, Margarita Marín Royoa, Santiago F. Marco Domenechb
a Servicio Neumología, Hospital General Universitario de Castellón, Castellón, Spain
b Servicio de Radiodiagnóstico, Hospital General Universitario de Castellón, Castellón, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Description of initial and 6 months CT according to signs of fibrosis at 6 months.
Tables
Full Text
Dear Editor,

COVID-19 disease caused by SARS-COV-2 has been a turning point in the humanity history. The clinical course has been variable since symptoms like common cold until bilateral pneumonia.1 Radiologically alterations in thoracic CT (computed tomography) have been ground-glass opacities with or without consolidations, crazy paving or interlobular septal thickening. The long-term alterations were ground glass, reticular pattern, traction bronchiectasis and parenchymal bands.1,2 If we compare with SARS-CoV, at 6 months, ground glass was observed in 76%, parenchymal bands in 59%, reticular pattern in 71% and consolidations in 3%. After 1.5 years, ground glass disappeared in most patients, persisting in 21% and parenchymal bands in 25%.3,4 15 years after primary infection, only 4% showed radiological alterations.5 To date, the risk factors described in COVID-19 infection associated with persistence of radiological alterations, including fibrosis, have been advanced age, male sex, type 2 diabetes, obesity, severity of the disease, smoking and chronic alcoholism.4,6,7 Alteration of diffusion capacity (DLCO) is the most frequent pulmonary functional alteration described and is directly related to the severity of the acute disease. The aim of our observational, prospective, single center study was to describe CT changes during COVID-19 pneumonia and evaluate fibrosis at 6 months describing changes in chest CT and functional respiratory impairment in all adult patients, non-vaccinate, being discharged from hospital after COVID-19 pneumonia. For further analysis, according to the findings of the control thoracic CT 6 months after discharge, patients will be divided into two groups: group 1 with pulmonary fibrosis and group 2 without pulmonary fibrosis. The presence on follow-up chest CT of parenchymal bands, irregular interfaces or traction bronchiectasis will be considered evidence of fibrosis. The study (version 5.0; December 2020) was approved by the Ethics Research Committee from Castellón General University Hospital.

We included 64 males (59%) and 45 females (41%) aged 6435±SD 13.43 years old. If we analyze clinical characteristics between groups, female sex (p-value 0.049), elderly patients (p-value 0.007), presence of arterial hypertension (p-value 0.036) and a longer hospital stay (p-value 0.022) are more frequent in fibrosis group. The comparison between initial CT and CT at 6 months shows that bilateral ground glass (OR 0.13; IC 0.04–0.44), unilateral (OR 0.06; IC 0.01–0.45) and bilateral (OR 0.01; IC 0–0.11) consolidations and bilateral crazy paving (OR 0.02; IC 0–0.16) and initial score, described by Francone et al.8 (OR 0.7; IC 0.64–0.77) decrease at 6 months in a statistically significant way. In contrast, architectural distortion (OR 12.8; IC 2.91–55.9) tend to increase over time (Table 1). If we compare the initial findings according to the presence of fibrosis or not at 6 months (Table 1) we can see that the presence of bronchial dilatation is more frequent in the fibrosis group (20% vs 3.4%), as well as the presence of subpleural curved line (40% vs 14%) and parenchymal bands (44% vs 17%). The initial score was higher in the fibrosis group (p-value 0.001).

Table 1.

Description of initial and 6 months CT according to signs of fibrosis at 6 months.

  Initial CT6 months CTUnivariant logistic regressionInitial vs 6 months CT N=109
Variables  N=109  Non fibrosisN=59  FibrosisN=50  p-Value  N=109  Non fibrosisN=59  FibrosisN=50  p-Value  OR  CI  p-Value 
Ground-grass opacity, n (%)
No  3 (2.8%)  1 (1.7%)  2 (4.0%)  0.8  19 (17%)  16 (27%)  3 (6.0%)  0.003     
Unilateral  3 (2.8%)  2 (3.4%)  1 (2.0%)    7 (6.4%)  6 (10%)  1 (2.0%)  0.37  0.06, 2.27  0.3 
Bilateral  103 (94%)  56 (95%)  47 (94%)    83 (76%)  37 (63%)  46 (92%)  0.13  0.04, 0.44  0.001 
Consolidaction, n (%)
No  60 (55%)  38 (64%)  22 (44%)  0.10  107 (98%)  58 (98%)  49 (98%)  0.7     
Unilateral  10 (9.2%)  4 (6.8%)  6 (12%)    1 (0.9%)  1 (1.7%)  0 (0%)  0.06  0.01, 0.45  0.007 
Bilateral  39 (36%)  17 (29%)  22 (44%)    1 (0.9%)  0 (0%)  1 (2.0%)  0.01  0.00, 0.11  <0.001 
Crazy paving, n (%)
No  70 (64%)  41 (69%)  29 (58%)  0.4  108 (99%)  59 (100%)  49 (98%)  0.5     
Unilateral  8 (7.3%)  3 (5.1%)  5 (10%)    0 (0%)  0 (0%)  0 (0%)  0.00  0.00, Inf  >0.9 
Bilatreal  31 (28%)  15 (25%)  16 (32%)    1 (0.9%)  0 (0%)  1 (2.0%)  0.02  0.00, 0.16  <0.001 
Reticular pattern, n (%)
No  91 (83%)  52 (88%)  39 (78%)  0.2  92 (85%)  57 (97%)  35 (71%)  <0.001     
Yes  18 (17%)  7 (12%)  11 (22%)    16 (15%)  2 (3.4%)  14 (29%)  0.88  0.42, 1.83  0.7 
Inverse halus, n (%)
No  106 (97%)  58 (98%)  48 (96%)  0.6  108 (100%)  59 (100%)  49 (100%)         
Yes  3 (2.8%)  1 (1.7%)  2 (4.0%)    0 (0%)  0 (0%)  0 (0%)         
Air bubble, n (%)
No  105 (96%)  58 (98%)  47 (94%)  0.3  105 (97%)  57 (97%)  48 (98%)  >0.9     
Yes  4 (3.7%)  1 (1.7%)  3 (6.0%)    3 (2.8%)  2 (3.4%)  1 (2.0%)  0.75  0.16, 3.43  0.7 
Bronchial dilatation, n (%)
No  97 (89%)  57 (97%)  40 (80%)  0.012  104 (95%)  59 (100%)  45 (90%)  0.017     
Yes  12 (11%)  2 (3.4%)  10 (20%)    5 (4.6%)  0 (0%)  5 (10%)  0.39  0.13, 1.14  0.086 
Bronchial wall thickening, n (%)
No  108 (99%)  59 (100%)  49 (98%)  0.5  109 (100%)  59 (100%)  50 (100%)         
Yes  1 (0.9%)  0 (0%)  1 (2.0%)    0 (0%)  0 (0%)  0 (0%)         
Prominent vessels, n (%)
No  107 (98%)  58 (98%)  49 (98%)  >0.9  107 (98%)  58 (98%)  49 (98%)  >0.9     
Yes  2 (1.8%)  1 (1.7%)  1 (2.0%)    2 (1.8%)  1 (1.7%)  1 (2.0%)  1.00  0.14, 7.23  >0.9 
Pleural thickening, n (%)
No  106 (97%)  58 (98%)  48 (96%)  0.6  108 (99%)  59 (100%)  49 (98%)  0.4     
Yes  3 (2.8%)  1 (1.7%)  2 (4.0%)    1 (0.9%)  0 (0%)  1 (2.0%)  0.33  0.03, 3.20  0.3 
Subpleural curved line, n (%)
No  81 (74%)  51 (86%)  30 (60%)  0.002  72 (66%)  57 (97%)  15 (30%)  <0.001     
Yes  28 (26%)  8 (14%)  20 (40%)    37 (34%)  2 (3.4%)  35 (70%)  1.49  0.83, 2.67  0.2 
Parenchimal bands, n (%)
No  77 (71%)  49 (83%)  28 (56%)  0.004  65 (60%)  58 (98%)  7 (14%)  <0.001     
Yes  32 (29%)  10 (17%)  22 (44%)    44 (40%)  1 (1.7%)  43 (86%)  1.63  0.93, 2.86  0.089 
Hypoatenuating line, n (%)
No  106 (97%)  56 (95%)  50 (100%)  0.2  108 (99%)  59 (100%)  49 (98%)  0.5     
Yes  3 (2.8%)  3 (5.1%)  0 (0%)    1 (0.9%)  0 (0%)  1 (2.0%)  0.33  0.03, 3.20  0.3 
Interphases sign, n (%)
No  107 (98%)  58 (98%)  49 (98%)  >0.9  107 (99%)  58 (100%)  49 (98%)  0.5     
Yes  2 (1.8%)  1 (1.7%)  1 (2.0%)    1 (0.9%)  0 (0%)  1 (2.0%)  0.50  0.04, 5.60  0.6 
Honey combing, n (%)
No  106 (97%)  58 (98%)  48 (96%)  0.6  106 (97%)  58 (98%)  48 (96%)  0.6     
Yes  3 (2.8%)  1 (1.7%)  2 (4.0%)    3 (2.8%)  1 (1.7%)  2 (4.0%)  1.00  0.20, 5.07  >0.9 
Traction bronchiectasis, n (%)
No  98 (90%)  56 (95%)  42 (84%)  0.1  89 (82%)  54 (92%)  35 (70%)  0.004     
Yes  11 (10%)  3 (5.1%)  8 (16%)    20 (18%)  5 (8.5%)  15 (30%)  2.00  0.91, 4.41  0.085 
Architecture distortion, n (%)
No  107 (98%)  59 (100%)  48 (96%)  0.2  88 (81%)  57 (97%)  31 (62%)  <0.001     
Yes  2 (1.8%)  0 (0%)  2 (4.0%)    21 (19%)  2 (3.4%)  19 (38%)  12.8  2.91, 55.9  <0.001 
Score8
Mean (SD)  11.65 (4.09)  10.59 (4.27)  12.90 (3.53)  0.001  5.26 (4.09)  3.53 (3.55)  7.30 (3.76)  <0.001  0.70  0.64, 0.77  <0.001 

Acronyms: computed tomography(CT), confidence interval (CI), odds ratio (OR).

If we compare the radiological findings at 6 months (Table 1) we can see that the presence of bilateral ground glass, reticular pattern, bronchial dilatation, subpleural curved line, parenchymal bands, traction bronchiectasis, architectural distortion and score were higher in the fibrosis group.

At 6 months, the proportion of patients with lung diffusion impairment (DLCO<80%) was 54.6% followed by forced vital capacity (FVC) decrease (28%) and forced expiratory volume in 1second (FEV1) decrease (21%). Although this decrease was greater in the fibrosis group at 6 months there were no significant differences between groups.

More than four years after SARS-CoV-2 pandemic, there are still unknowns to be resolved, such as the long-term sequelae and the associated risk factors. To this end, it is very important to identify, at an early stage, those patients will be more likely to present alterations over time. In accordance with the literature, we have found that older patients with comorbidities (specifically arterial hypertension) and longer hospital stay were significantly associated with presence of fibrosis at 6 months.6,9 In contrast to that published by Valenzuela C et al.10 in our study, female sex was associated with the fibrosis group. As published by Bakhsh N et al.11 and Fabbri L et al.,12 the most frequent initial radiological alteration was the presence of bilaterally ground glass (94%), bilateral consolidations (36%) followed by crazy paving (28%). We have described that the presence of bronchial dilatation, subpleural curved line and parenchymal bands in the initial CT are significantly associated with the fibrosis group at 6 months. As suggested by Yu M et al.6 they could be early predictors of pulmonary fibrosis. The same is described by Babar et al.13 and Bakhsh et al.11 where traction bronchiectasis, reticular pattern and septal thickening are associated with the fibrosis group. In evolutionary CT studies at 6 months and 1 year13 the presence of ground glass and consolidations decrease with time. In our case, the decrease in ground glass and consolidations of the initial CT compared to CT at 6 months was statistically significant (p-value<0.001).

Functional tests at 6 months usually show a decrease in diffusion related to radiological involvement in 39% and 31% at 12 months.14,15 In our study, 55% have decrease in DLCO. In the fibrosis group the decrease was higher (64%).

There are limitations to this study. The first is the low number of patients collected. Second, there is no histological confirmation of fibrosis, although the radiographic findings on thoracic CT are highly suggestive. Last one, only patients who have been hospitalized have been included in the study, which means that they have presented a more severe infection, and this could lead to a selection bias for the distribution and extension of pulmonary lesions. Therefore, these findings could not be generalized to the entire COVID-19 infected population.

To conclude, 45% of patients hospitalized for pneumonia secondary to SARS-CoV-2 present signs of fibrosis at 6 months. These findings confirm the need for follow-up of patients over a longer period to clarify whether these changes will persist over time.

Funding

This study has not been funded.

Authors’ contributions

Cuenca Peris, Selene has contributed to the literature search, study design, data interpretation, has done all study assessments. Marco Domenech, Santiago F has contributed to interpretate all tomographic images and Marín Royo, Margarita, has contribute to interpretate lung functional studies. All authors had contributed to article writing and editing and approved its submission.

Conflicts of interest

The results presented have not been published previously. The authors declare no competing interests.

References
[1]
A. Fabre, J.R. Hurst, S. Ramjug.
European Respiratory Society (ERS) monographs.
(2021),
[2]
E. Guinto, F.V. Gerayeli, R.L. Eddy, H. Lee, S. Milne, D.D. Sin.
Post-COVID-19 dyspnoea and pulmonary imaging: a systematic review and meta-analysis.
Eur Respir Rev, 32 (2023), pp. 220253
[3]
C.C. Huntley, K. Patel, S.E. Bil Bushra, F. Mobeen, M.N. Armitage, A. Pye, et al.
Pulmonary function test and computed tomography features during follow-up after SARS, MERS and COVID-19: a systematic review and meta-analysis.
[4]
A. Watanabe, M. So, M. Iwagami, K. Fukunaga, H. Takagi, H. Kabata, et al.
One-year follow-up CT findings in COVID-19 patients: a systematic review and meta-analysis.
Respirology, 27 (2022), pp. 605-616
[5]
H.H. Hsu, C. Tzao, C.P. Wu, W.-C. Chang, C.-L. Tsai, H.-J. Tung, et al.
Correlation of high-resolution CT, symptoms, and pulmonary function in patients during recovery from severe acute respiratory syndrome.
Chest, 126 (2004), pp. 149-158
[6]
M. Yu, Y. Liu, D. Xu, R. Zhang, L. Lan, H. Xu.
Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia.
Korean J Radiol, 21 (2020), pp. 746-755
[7]
A.S. Ojo, S.A. Balogun, O.T. Williams, O. Ojo.
Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies.
Pulm Med, 2020 (2020), pp. 6175964
[8]
M. Francone, F. Iafrate, G.M. Masci, S. Coco, F. Cilia, L. Manganaro, et al.
Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis.
Eur Radiol, 30 (2020), pp. 6808-6817
[9]
I. Stewart, J. Jacob, P.M. George, P.L. Molyneaux, J.C. Porter, R.J. Allen, et al.
Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD post-COVID-19 study.
Am J Respir Crit Care Med, 207 (2023), pp. 693-703
[10]
C. Valenzuela, L. de la Fuente, S. Hernández, M.J. Olivera, C. Molina, N. Montes, et al.
Persistent pulmonary abnormalities after 18 months of SARS-CoV-2 pneumonia.
Radiologia (Engl Ed), 66 (2024), pp. S47-S56
[11]
N. Bakhsh, M. Banjar.
COVID-19 chest manifestation on CT scan and associated risk factors for developing pulmonary fibrosis.
[12]
L. Fabbri, S. Moss, F.A. Khan, W. Chi, J. Xia, K. Robinson, et al.
Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis.
[13]
M. Babar, H. Jamil, N. Mehta, A. Moutwakil, T.Q. Duong.
Short- and long-term chest-CT findings after recovery from COVID-19: a systematic review and meta-analysis.
Diagnostics (Basel), 14 (2024), pp. 621
[14]
J.H. Lee, J.J. Yim, J. Park.
Pulmonary function and chest computed tomography abnormalities 6–12 months after recovery from COVID-19: a systematic review and meta-analysis.
Respir Res, 23 (2022), pp. 233
[15]
R. Torres-Castro, L. Vasconcello-Castillo, X. Alsina-Restoy, L. Solís-Navarro, F. Burgos, H. Puppo, et al.
Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis.
Pulmonology, 27 (2021), pp. 328-337
Copyright © 2025. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos